RMS (relapsing multiple sclerosis) and PPMS (primary progressive multiple sclerosis) are two broad categories of multiple sclerosis that behave very differently. RMS, which includes relapsing-remitting MS (RRMS), involves distinct flare-ups of symptoms followed by periods of partial or full recovery. PPMS involves a steady, gradual worsening of neurological function from the very beginning, with no clear relapses. About 85% of people diagnosed with MS start with a relapsing form, while roughly 15% are diagnosed with PPMS from the outset.
How Relapsing MS Works
In relapsing MS, the immune system periodically crosses from the bloodstream into the brain and spinal cord, where it attacks the protective coating around nerve fibers. Each attack creates a focal area of damage called a lesion. These episodes produce new or worsening neurological symptoms, anything from vision loss and numbness to difficulty walking or problems with coordination. The symptoms then partially or fully fade as inflammation subsides and the nervous system attempts to repair itself.
RRMS is the most common form and typically appears in a person’s 30s. Recovery from a relapse isn’t instant. The median time to recover from a flare-up is about 111 days, and 80% of people who recover do so within the first six months. In clinical studies, around 84% of participants returned to their previous baseline after a relapse, though when recovery was tracked more rigorously over 12 or 24 weeks, that number dropped to roughly 52-55%. Over time, incomplete recoveries can leave behind lasting disability even between relapses.
How Primary Progressive MS Works
PPMS looks fundamentally different from the start. Instead of attacks and recoveries, people with PPMS experience a slow, continuous decline in neurological function. Walking gradually becomes harder, balance worsens, or cognitive abilities erode steadily over months and years. To receive a PPMS diagnosis, a person needs to show at least one year of gradual worsening.
PPMS tends to begin later, typically in a person’s 40s. In a large pooled study of nearly 600 PPMS patients followed for an average of 4.4 years, disability scores increased from a baseline average of 4.3 to 5.5 on the standard neurological disability scale. That translates to roughly a quarter-point increase per year. To put that in practical terms, someone who starts out needing a cane intermittently might progress over several years to needing one constantly or requiring a wheelchair for longer distances.
What Drives Each Type Biologically
The underlying biology helps explain why these two forms behave so differently. In relapsing MS, the main driver is peripheral immune cells, particularly certain white blood cells, becoming activated and flooding into the central nervous system through a compromised blood-brain barrier. This creates intense but localized inflammation. It’s also why the many medications approved for RRMS work: they target immune cell activation, reproduction, or migration into the brain.
PPMS is driven by something different. The blood-brain barrier stays relatively intact, but a slow-burning inflammatory process takes hold behind it. Immune cells already resident in the brain, particularly a type called microglia, become chronically activated. This “smoldering” inflammation spreads not just in visible lesions but diffusely through tissue that looks normal on standard imaging. Chronic oxidative damage, iron accumulation, and energy failure within nerve cells all compound the problem. Because the inflammation is trapped behind the blood-brain barrier rather than flooding in from outside, treatments designed to block immune cells from entering the brain have far less effect.
The Line Between Them Is Blurrier Than It Seems
The traditional view treats relapsing and progressive MS as distinct diseases, but newer research suggests they’re better understood as a spectrum. Even in people with RRMS who are on effective treatment and have no relapses at all, disability can still quietly accumulate. This phenomenon, called progression independent of relapse activity, suggests that the same smoldering process seen in PPMS is also at work in relapsing MS, just overshadowed by the more dramatic flare-ups.
Studies tracking long-term outcomes have found that suppressing relapses with medication doesn’t always prevent long-term disability. The implication is striking: relapsing and progressive MS may not be fundamentally different diseases but rather the same disease with different balances of acute inflammation versus chronic, slow-burn nerve damage. The relapsing phase and the progressive phase differ in degree, not in kind.
This also shows up in the transition from RRMS to secondary progressive MS (SPMS). Over time, many people with RRMS shift into a progressive pattern where disability accumulates steadily regardless of relapses. About 10% of RRMS patients convert to SPMS within 10 years, 50% by 20 years, and over 90% by 30 years. Once someone reaches the secondary progressive stage, their disease course looks remarkably similar to PPMS.
How Each Type Is Diagnosed
Doctors use the McDonald Criteria to diagnose both forms. For relapsing MS, the key requirements are evidence of lesions in at least two different areas of the central nervous system (dissemination in space) that developed at different times (dissemination in time). MRI can demonstrate this by showing both active, newly inflamed lesions and older ones simultaneously, or by comparing scans taken months apart.
Diagnosing PPMS is trickier because there are no clear-cut relapses to point to. It requires documented gradual worsening over at least one year, supported by MRI findings and often spinal fluid analysis. The MRI and spinal fluid testing play a larger role in PPMS diagnosis precisely because the clinical picture is less obvious without distinct attacks.
Treatment Differences
The treatment gap between these two forms is significant. For relapsing MS, there are more than a dozen approved disease-modifying therapies. These include injectable medications, oral drugs, and infusion therapies that work by dampening or redirecting the immune system’s attacks on the nervous system. Many are highly effective at reducing relapse rates and slowing the formation of new lesions.
For PPMS, only one disease-modifying therapy has FDA approval: ocrelizumab, which received its approval in 2017 as the first treatment specifically indicated for this form. The scarcity of options reflects the core biological challenge. Anti-inflammatory drugs that work well against the immune system attacks driving RRMS have largely failed in PPMS trials because the inflammation in PPMS is a different kind, confined behind the blood-brain barrier and driven by resident brain immune cells rather than invading ones. Beyond ocrelizumab, treatment for PPMS focuses heavily on managing symptoms like pain, spasticity, fatigue, and mobility, often with the help of physical therapy and assistive devices.